Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 May 16;13(1):LMT67.
doi: 10.2217/lmt-2023-0010. eCollection 2024.

Prognostic significance of systemic immune inflammatory index in NSCLC: a meta-analysis

Wen-Hua Chen  1 , Jing-Jing Shao  2 , Ying Yang  2 , Yun Meng  3 , Sheng Huang  3 , Rong-Fang Xu  3 , Ji-Bin Liu  2 , Jian-Guo Chen  2 , Qin Wang  2 , Hai-Zhen Chen  1   2
Affiliations
Review

Prognostic significance of systemic immune inflammatory index in NSCLC: a meta-analysis

Wen-Hua Chen et al. Lung Cancer Manag. .

Abstract

Aim: The aim of this meta-analysis was to investigate the relationship between the baseline systemic immune inflammatory index (SII) and prognosis in patients with NSCLC. Materials & methods: The relation between pretreatment SII and overall survival, disease-free survival, cancer-specific survival, progression-free survival and recurrence-free survival in NSCLC patients was analyzed combined with hazard ratio and 95% CI. Results: The results showed that high SII was significantly correlated with overall survival and progression-free survival of NSCLC patients, but not with disease-free survival, cancer-specific survival and recurrence-free survival. Conclusion: The study suggests that a higher SII has association with worse prognosis in NSCLC patients. PROSPERO registration number: CRD42022336270.

Keywords: NSCLC; baseline; meta-analysis; prognosis; systemic immune inflammation index (SII).

PubMed Disclaimer

Conflict of interest statement

The authors have no competing interests or relevant affiliations with any organization or entity with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

Figures

Figure 1.
Figure 1.
Flow chart of the included studies.
Figure 2.
Figure 2.
Forrest plots of studies evaluating hazard ratio with 95% CI of systemic immune inflammatory index for overall survival (A), progression-free survival (B) and disease-free survival (C). Weights are from random-effects model.
Figure 3.
Figure 3.
Sensitivity analysis of (A) overall survival and (B) progression-free survival.
Figure 4.
Figure 4.
Publication bias assessment. (A) Funnel plot for publication bias in overall survival; (B) Funnel plot adjusted by the trim and fill method in overall survival; (C) Funnel plot for publication bias in progression-free survival.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Ferlay J, Soerjomataram I, Dikshit Ret al. . Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int. J. Cancer 136(5), E359–E386 (2015). - PubMed
    1. Sung H, Ferlay J, Siegel RLet al. . Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 71(3), 209–249 (2021). - PubMed
    1. de Goede OM, Nachun DC, Ferraro NMet al. . Population-scale tissue transcriptomics maps long non-coding RNAs to complex disease. Cell 184(10), 2633–2648; e19 (2021). - PMC - PubMed
    1. Yang R, Chang Q, Meng Xet al. . Prognostic value of systemic immune-inflammation index in cancer: a meta-analysis. J. Cancer 9(18), 3295–3302 (2018). - PMC - PubMed
    1. Hu B, Yang XR, Xu Yet al. . Systemic immune-inflammation index predicts prognosis of patients after curative resection for hepatocellular carcinoma. Clin. Cancer Res. 20(23), 6212–6222 (2014). - PubMed

LinkOut - more resources